A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

BACKGROUND: Lung cancer is most common among older individuals. However, polypharmacy and comorbidities, which are also more common in older individuals, can limit treatment options. Previous studies suggest that afatinib can be used safely and effectively in elderly patients. This study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Minegishi, Yuji, Yamaguchi, Ou, Sugawara, Shunichi, Kuyama, Shoichi, Watanabe, Satoshi, Usui, Kazuhiro, Mori, Masahide, Hataji, Osamu, Nukiwa, Toshihiro, Morita, Satoshi, Kobayashi, Kunihiko, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919080/
https://www.ncbi.nlm.nih.gov/pubmed/33648453
http://dx.doi.org/10.1186/s12885-021-07861-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919080/
https://www.ncbi.nlm.nih.gov/pubmed/33648453
http://dx.doi.org/10.1186/s12885-021-07861-1

Ejemplares similares